Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 2.7. It has been cited 69 times, with 61 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.637
From this paper's citation signal
Citation Network Contribution
2.0
From 47 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 61 citers.
Memorial Sloan-Kettering Cancer Center
Grant: P30 CA008748
Ono Pharmaceutical
Grant: N/A
National Institutes of Health
Grant: P30 CA016672
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
FWCI
8.70
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy
Additional file 1 of Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy